It can take a long time to create a new vaccine and at the same time, there have been many evolutions and new strains of the ...

By updating the genetic code inside mRNA vaccines every year, scientists can keep population-level immunity aligned with ...

The inequitable distribution of vaccines during the COVID-19 pandemic was the final proof of the need for more home-grown ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

A new lipid nanoparticle could make mRNA vaccines more powerful and potentially lower the cost per vaccine dose.

Adrian Towse, Emeritus Director and Visiting Senior Research Fellow at OHE looks back at his journey and impact in health economics research.

Q3 2025 Management View CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic fibrosis (CF), showed "treatment with inhaled ...

Pfizer has fended off Nova Nordisk for control of the next-gen weight-loss drug developer Metsera. Meanwhile, Resmed watches ...

In his new book, 'Fair Doses,' epidemiologist Seth Berkley discusses what went right -- and wrong -- with COVID vaccine ...

Epidemiologist Michael Osterholm talks about efforts by the Center for Infectious Disease Research and Policy to inform ...